公开(公告)号：US20130225574A1

公开(公告)日：2013-08-29

申请号：US13773947

申请日：2013-02-22

Applicant: Novartis AG

Inventor： Giorgio CARAVATTI ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Frederic STAUFFER ,  Frank Hans SEILER ,  Clive MCCARTHY ,  Heinrich RUEEGER

IPC: C07D413/14 ,  A61K31/5377 ,  A61K45/06

CPC classification number: C07D498/04 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/14

Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Abstract translation: 本发明涉及作为PI3K（磷脂酰肌醇-3-激酶）抑制剂的恶唑烷-2-酮取代的嘧啶化合物及其药物组合物，其制备方法和用于治疗依赖于 PI3K。

公开(公告)号：US20180185341A1

公开(公告)日：2018-07-05

申请号：US15516443

申请日：2015-10-02

Applicant: Novartis AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNÖPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61K31/496 ,  A61P35/00

CPC classification number: A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20190231760A1

公开(公告)日：2019-08-01

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNOPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20180140582A1

公开(公告)日：2018-05-24

申请号：US15876619

申请日：2018-01-22

Applicant: NOVARTIS AG

Inventor： Jun CAO ,  Bernhard ERB ,  Robin Alec FAIRHURST ,  Arnaud GRANDEURY ,  Shinji HATAKEYAMA ,  Magdalena KOZICZAK-HOLBRO ,  Xinzhong LAI ,  Philipp LUSTENBERGER ,  Bernd Ulrich RIEBESEHL ,  Nicola TUFILLI ,  Thomas ULLRICH ,  Xiang WU ,  Jianguang ZHOU

IPC: A61K31/428 ,  C07C53/10 ,  C07D277/68 ,  A61K45/06 ,  A61K31/167

CPC classification number: A61K31/428 ,  A61K31/167 ,  A61K45/06 ,  C07B2200/07 ,  C07C53/10 ,  C07D277/68 ,  Y02P20/55

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

公开(公告)号：US20190076412A1

公开(公告)日：2019-03-14

申请号：US16190087

申请日：2018-11-13

Applicant: NOVARTIS AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Thomas KNÖPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Pierre NIMSGERN ,  Sebastien RIPOCHE ,  Jing XIONG ,  Bo HAN ,  Can WANG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/55 ,  A61K31/496

Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220401422A1

公开(公告)日：2022-12-22

申请号：US17241981

申请日：2021-04-27

Applicant: Novartis AG

Inventor： Robin Alec FAIRHURST ,  Christine FRITSCH ,  Marc GERSPACHER ,  Jürgen Hans-Hermann HINRICHS ,  Jean-Baptiste Georges Armand LANGLOIS ,  Catherine LEBLANC ,  Tengfei LI ,  Edwige Liliane Jeanne LORTHIOIS ,  Christophe MURA ,  Cristina Montserrat NIETO-OBERHUBER ,  Milen TODOROV ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN

IPC: A61K31/437 ,  A61P35/00 ,  C07D471/10 ,  C07D471/20 ,  A61K31/4747 ,  C07D491/20 ,  C07D491/22 ,  A61K31/4375 ,  C07D495/20 ,  C07D495/22 ,  A61K31/436 ,  A61K31/675 ,  A61K31/155 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/635 ,  A61K31/53

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

公开(公告)号：US20200261444A1

公开(公告)日：2020-08-20

申请号：US16347194

申请日：2017-11-01

Applicant: NOVARTIS AG

Inventor： Robin Alec FAIRHURST ,  Diana GRAUS PORTA ,  Jacqueline KINYAMU-AKUNDA ,  Andreas Joerg MAHL ,  Luigi MANENTI ,  Andreas WEISS ,  Armin WOLF ,  Kuno WUERSCH

IPC: A61K31/496 ,  A61K31/14

Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.